The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).
 
Ira Seth Winer
Research Funding - Oncoceutics
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); EcoR1 Capital; Genome Insight; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Dynavax Technologies (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Erin Lynn Schenk
Honoraria - Horizon CME; Ideology Health; MECC Global Meetings; MJH Life Sciences; OncLive; OncLive; Regeneron; Takeda
Consulting or Advisory Role - Actinium Pharmaceuticals; Bionest partners; ClearView Healthcare Partners; G1 Therapeutics; Guidepoint Global; Prescient Healthcare Group; Regeneron; Regeneron
 
Patricia LoRusso
Stock and Other Ownership Interests - BAKX Therapeutics
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Salarius Pharmaceuticals; Scenic Biotech; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Oladapo O. Yeku
Stock and Other Ownership Interests - hC Bioscience
Honoraria - Medscape
Consulting or Advisory Role - Gimv; hC Bioscience; TigaTx
Patents, Royalties, Other Intellectual Property - Dr. Yeku has a patent for MUC16 Directed Antibodies for therapeutic applications pending and a patent for Human Artificial Chromosomes for therapeutic applications pending.
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Nadine Jahchan
Employment - Pionyr
Stock and Other Ownership Interests - ORIC Pharmaceuticals; Pionyr
Research Funding - Gilead Sciences
Travel, Accommodations, Expenses - Pionyr
 
Matthew Myers
Employment - Pionyr
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences; Pionyr
 
Linda Liang
Employment - Pionyr
Stock and Other Ownership Interests - Bristol-Myers Squibb/Medarex; Merck
Patents, Royalties, Other Intellectual Property - Pionyr
 
Denise Deegan
Employment - Pionyr
Stock and Other Ownership Interests - Pionyr
 
Lynnae Jackson
Employment - Pionyr
Stock and Other Ownership Interests - Pionyr
 
Yunfeng Li
Employment - Apellis Pharmaceuticals (I); Pionyr
Stock and Other Ownership Interests - Apellis Pharmaceuticals (I); Pionyr
 
Len Reyno
Employment - Pionyr
Leadership - Pionyr
Stock and Other Ownership Interests - Pionyr
 
Marc Charles Chamberlain
Employment - Pionyr
Stock and Other Ownership Interests - Pionyr